Peroxisome proliferator-activated receptor γ (PPARγ) has been shown to be a therapeutic target for preeclampsia (PE). Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional secretory protein involved in regulating lipid metabolism and angiogenesis in various tissues. However, the expression of PPARγ and ANGPTL4 and their interaction in PE remain elusive. Here we showed that PPARγ agonist rosiglitazone upregulated the expression and secretion of ANGPTL4 in a dose-dependent manner in HTR8/SVneo cells, human umbilical vein endothelial cells (HUVECs) and placental explants. More importantly, we confirmed that the PPARγ/retinoid X receptor α heterodimer specifically binds to the ANGPTL4 promoter region and enhances its transcriptional activity. In addition, the levels of ANGPTL4 and PPARγ activators in the serum and their expression in placental tissues were significantly reduced in preeclamptic patients compared with normal pregnant subjects. Furthermore, functional studies demonstrated that ANGPTL4 mediates the facilitative effects of the PPARγ agonist on the survival, proliferation, migration and invasion of HTR8/SVneo cells, placental explants outgrowth and angiogenesis in HUVECs. Taken together, our results suggest that ANGPTL4 is a potential target gene for PPARγ and mediates the protective role of PPARγ activators in the pathogenesis of PE.
PE remain largely unclear, it is generally accepted that the placenta is of great importance in the pathogenesis of PE because removal of the placenta can eradicate clinical symptoms in the patients with PE. 2 At present, a growing body of evidence indicates that abnormally shallow placentation in early pregnancy is mainly responsible for the onset of PE. 3 Excessive apoptosis of trophoblast cells, poor invasion of the uterine wall by trophoblasts and impaired remodelling of spiral arteries at the maternal-foetal interface are major abnormal placentation events that are closely related to PE. A wide range of growth factors and hormones are also believed to be involved in the intricate regulation of these events. Peroxisome proliferator-activated receptors, including PPARα, PPARβ/δ and PPARγ, are ligand-activated transcription factors that regulate a number of genes associated with cell differentiation and proliferation. 4 PPARγ has an important role in the differentiation of complicated trophoblast lineages and normal vascular function. [5] [6] [7] In addition, recent studies have shown that serum concentrations of endogenous activators of PPARγ are dramatically decreased in severe PE patients compared with healthy pregnant women, 8 and
PPARγ may serve as a novel therapeutic target for PE. 9 Nevertheless, the molecular mechanisms of the protective roles of PPARγ in PE remain largely unknown.
Angiopoietin-like protein 4 (ANGPTL4), a secretory glycoprotein, is a member of the angiopoietin family. 10 Previous studies have suggested that ANGPTL4 is a multifunctional factor involved in the regulation of lipid metabolism, wound healing and angiogenesis. 11, 12 Furthermore, it has been reported that activation of PPARγ induces the expression and secretion of ANGPTL4. 13, 14 However, the expression and secretion of ANGPTL4 in PE has not been investigated. In addition, it remains unknown whether a regulatory interaction between ANGPTL4 and PPARγ exists in PE.
Here, we investigated the effects of the PPARγ agonist rosiglitazone on the expression and secretion of ANGPTL4 and the molecular mechanisms underlying these effects in HTR8/SVneo cells, human umbilical vein endothelial cells (HUVECs) and placental explants. Moreover, we explored the expression of ANGPTL4 and PPARγ in placental tissue and serum as well as their potential correlation in preeclamptic patients and healthy subjects. To further identify the latent roles of ANGPTL4 and PPARγ in PE, a variety of functional studies were performed using cell lines and placental explant models.
in Figures 1a-c and Supplementary Figure 1a , rosiglitazoneinduced ANGPTL4 mRNA and protein expression and its secretion in a concentration-dependent manner. Rosiglitazone also induced the mRNA and protein expression of PPARγ in a similar manner (Figures 1a-c) . The rosiglitazoneinduced expression of ANGPTL4 and PPARγ was also demonstrated by immunofluorescence staining (Figure 1d ).
To further determine the role of PPARγ in the rosiglitazoneinduced expression and secretion of ANGPTL4, HTR8/SVneo cells, HUVECs and placental explants were transfected with control siRNA (si-Con) or PPARγ siRNA (si-PPARγ) and treated with 1 μM rosiglitazone. The results showed that silencing of PPARγ expression inhibited the effects of rosiglitazone on ANGPTL4 protein and mRNA expression as well as its secretion (Figures 1e-g and Supplementary  Figure 1b) . The same results were confirmed in the cell lines and explants through immunofluorescence staining (Figure 1h and Supplementary Figure 1c) . These data suggest that PPARγ is indispensable for the rosiglitazone-induced expression and secretion of ANGPTL4.
ANGPTL4 is a direct transcriptional target of PPARγ. Activated PPARγ regulates gene expression via heterodimerizing with retinoid X receptors (RXRs) and binding to the peroxisome proliferator-responsive element (PPRE) of target genes. 15 Given that PPARγ is implicated in the regulation of ANGPTL4 expression and secretion, we speculated that a PPRE likely exists in the promoter region of ANGPTL4 for its transactivation. To test this hypothesis, we analysed the human ANGPTL4 5'-flanking region and identified three putative PPREs, namely PPRE1 (−1822/ − 1808), PPRE2 (−809/ − 795) and PPRE3 (−233/ − 209), located upstream of the ANGPTL4 transcription start site ( Figure 2a) . Next, to determine whether PPARγ binds to these regions, a chromatin immunoprecipitation (ChIP) assay was performed The PPARγ/retinoid X receptor α (PPARγ/RXRα) heterodimer is required for placental development. 16 To investigate whether RXRα is involved in the rosiglitazone-induced expression and secretion of ANGPTL4, HTR8/SVneo cells, HUVECs and placental explants were transfected with control siRNA (si-Con) or RXRα siRNA (si-RXRα) and treated with rosiglitazone. As shown in Figures 2c-e, silenced RXRα expression abolished the effects of rosiglitazone on ANGPTL4 protein and mRNA expression, as well as its secretion. Surprisingly, the rosiglitazone-induced PPARγ protein and mRNA expression were not affected by treatment with si-RXRα (Figures 2c and d ). These results demonstrate that RXRα is a prerequisite for rosiglitazone-induced ANGPTL4 expression. Subsequently, to further determine whether RXRα also binds to the PPRE3 in ANGPTL4 promoter region, ChIP assays were carried out in HTR8/SVneo cells, HUVECs and placental explants. The data showed that both PPARγ and RXRα bound to PPRE3 in the ANGPTL4 promoter (Figure 2f ). Together, these results indicate that rosiglitazone stimulates ANGPTL4 expression via regulating the binding of the PPARγ/ RXRα heterodimer to its promoter. The expression and circulating activators of PPARγ and the expression and secretion of ANGPTL4 are decreased in PE. As shown in Supplementary (Figure 3c ). Because the PPARγ agonist rosiglitazone induces the mRNA and protein expression of PPARγ in a concentrationdependent way in placental explants, we speculated that circulating activators of PPARγ were decreased in PE subjects compared with normal pregnant women. To prove this hypothesis, placental explants were treated with serum from normal controls (n = 5) and PE subjects (n = 5). The mRNA expression of PPARγ and ANGPTL4 as well as the secretion of ANGPTL4 were upregulated by serum from both PE and control subjects in a concentration-dependent manner (Figures 3j and k) and increased in normal pregnant women compared with PE ( Figure 3l and Supplementary Figure 2 ). In addition, PPARγ mRNA was significantly reduced in preeclamptic placentae compared with normal placentae (Figure 3a ). Based on the above results, our hypothesis that circulating activators of PPARγ in PE are decreased may be correct.
Next, correlation analysis revealed a positive relationship between the mRNA level of PPARγ and the mRNA level and secretion of ANGPTL4 in PE (n = 30) and normal pregnant women (n = 30) (Figures 3f-i) , suggesting a functional interaction between PPARγ and ANGPTL4 in vivo. Given that serum from PE and control subjects stimulated PPARγ mRNA expression in a concentration-dependent manner, the mRNA level of PPARγ in placental tissues should be an indicator of circulating activators of PPARγ in serum. Together with the results shown in Figures 3f-i, we hypothesised that circulating PPARγ activators positively correlate with the secretion of ANGPTL4 in normal pregnant and PE women. Taken together, the expression and circulating activators of PPARγ and the expression and secretion of ANGPTL4 are decreased in PE, and the reduced expression and secretion levels of ANGPTL4 may result from a decrease in circulating activators of PPARγ in serum.
ANGPTL4 mediates rosiglitazone-induced trophoblast cell survival and proliferation. Excessive apoptosis of trophoblast cell is a major abnormal placentation event involved in PE. 3 Oxidative stress is responsible for increased trophoblast cell apoptosis. 17 Therefore, we determined the effects of ANGPTL4 and PPARγ on trophoblast cell survival. HTR8/SVneo cells transfected with control siRNA (si-Con) or ANGPTL4 siRNA (si-ANGPTL4) were treated with 150 μM hydrogen peroxide and 1 μM rosiglitazone for 48 hours. Controls were stimulated with 150 μM hydrogen peroxide and 100 nM recombinant human ANGPTL4 (rhANGPTL4). Subsequently, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) assays were performed to determine the rate of cellular apoptosis. Rosiglitazone and rhANGPTL4 dramatically inhibited trophoblast cell apoptosis induced by hydrogen peroxide, and the deletion of ANGPTL4 abolished the antiapoptotic effects of rosiglitazone (Figure 4a and Supplementary Figure 3 ). At the same time, the expression of molecular markers associated with apoptosis, such as Bax, cleaved PARP, caspase-9, cleaved caspase-9, caspase-3 and cleaved caspase-3, was also reduced in cells treated with rosiglitazone and rhANGPTL4 compared with the control (Figures 4b and c) . Furthermore, the expression of CK7 (a marker of trophoblast), PPARγ, ANGPTL4 and caspase-3 was assessed through IHC in preeclamptic placentae and normal controls. The results indicated that caspase-3 expression was increased in preeclamptic placentae with lower PPARγ and ANGPTL4 expression compared with normal placentae (Figure 4g) .
Next, the roles of ANGPTL4 and PPARγ in trophoblast cell proliferation were assessed using a cell proliferation assay. Similarly, rosiglitazone and rhANGPTL4 significantly promoted trophoblast cell proliferation compared with controls, and ablation of ANGPTL4 blocked the effects of rosiglitazone (Figure 4d ). In addition, the expression of cell proliferationrelated genes, such as Cyclin D1, Bcl-2, c-Myc and pHH3, was clearly upregulated in cells treated with rosiglitazone and rhANGPTL4 compared with controls (Figures 4e and f) . Consistent with these results, decreased expression of PPARγ, ANGPTL4 and cyclin D1 was observed in PE placentae compared with controls by IHC (Figure 4g ). In conclusion, these data indicate that ANGPTL4 is essential for the PPARγ agonist-induced survival and proliferation of trophoblasts.
ANGPTL4 is important for the migration and invasion of trophoblast cell and placental explant outgrowth induced by the PPARγ agonist. To elucidate the roles of ANGPTL4 and PPARγ in trophoblast cells migration and invasion, transwell invasion and wound-healing assays were executed in HTR8/SVneo cells transfected with si-ANGPTL4 or si-Con and control cells. Rosiglitazone and rhANGPTL4 exhibited similar roles in the migration and invasion of trophoblast cells compared with control cells, and silenced ANGPTL4 abolished the effects of rosiglitazone (Figures 5a,b and d) . (Figures 5c and e) .
To further verify the physiological roles of PPARγ and ANGPTL4 in trophoblast cell invasion and migration, placenta villous explants were performed. As expected, rosiglitazone and rhANGPTL4 markedly promoted the outgrowth of placenta villous explants compared with the controls, and deletion of ANGPTL4 abolished the effects of rosiglitazone (Figures 5f and g ). The expression of MMP-2 and MMP-9 was also measured by gelatin zymography, which indicated that their expression, as well as that of TIMP-1 and TIMP-2 was consistent with previous results (Figure 5h) . Furthermore, IHC analysis revealed decreased expression of MMP-2 and MMP-9 in preeclamptic placentae (n = 30) compared with normal placentae (n = 30) (Figure 5i) . These observations collectively demonstrate that ANGPTL4 mediates the PPARγ agonist-induced migration and invasion of trophoblast cells and placental explant outgrowth via regulating MMP-2 and MMP-9.
ANGPTL4 is involved in PPARγ agonist-induced angiogenesis. Limited remodelling of the spiral arteries is a main pathological feature of PE. 3 To explore the roles of PPARγ and ANGPTL4 in angiogenesis, a tube formation assay was performed on HUVECs transfected with si-Con or si-ANGPTL4 and control cells. Rosiglitazone and rhANGPTL4 distinctly increased the total tube length, total number of tubes and total branch points compared with controls, but depletion of ANGPTL4 eliminated the effects of rosiglitazone in angiogenesis (Figures 6a and b) . Moreover, the expression and secretion of vascular endothelial growth factor (VEGF) was examined via qRT-PCR, western blot and ELISA, which yielded results similar to those from the tube formation assay (Figure 6c) . Eventually, the expression of CD31 (an indicator of vascularity) and VEGF in placental tissues was evaluated by IHC, which indicated their decreased expression in preeclamptic placentae (n = 30) compared with normal placentae (n = 30) (Figure 6d ). All in all, these data suggest that ANGPTL4 is an important mediator of PPARγ agonist-induced angiogenesis.
Discussion
In the present study, we show that PPARγ is a prerequisite for the PPARγ agonist-induced expression and secretion of ANGPTL4 in HTR8/SVneo cells, HUVECs and placental explants in a concentration-dependent manner. We also identify ANGPTL4 as a direct transcriptional target of PPARγ and demonstrate for the first time that decreased expression and secretion of ANGPTL4 may result from a decrease in circulating PPARγ activators in preeclamptic patients compared with normal pregnant subjects. In addition, we provide evidence that ANGPTL4 mediates the facilitative effects of PPARγ agonist-induced survival, proliferation, migration and invasion in trophoblast cells, as well as outgrowth in placental explants and angiogenesis in HUVECs. In conclusion, these findings indicate that ANGPTL4 is involved in the protective effects of PPARγ activators on the pathogenesis of PE (Figure 7) .
PPARs are ligand-activated transcriptional factors that regulate many genes associated with cell proliferation and differentiation. 4 PPARγ is crucial for the differentiation of intricate trophoblast lineages and normal vascular function. [5] [6] [7] Moreover, previous studies have demonstrated that ANGPTL4 serves as a multifunctional factor involved in the regulation of lipid metabolism, wound healing and angiogenesis. 11, 12 However, it is not clear whether the expression of ANGPTL4 is regulated by PPARγ agonists in HTR8/SVneo cells, HUVECs and placental explants. Our study demonstrates that the expression and secretion of ANGPTL4 in these cells and placental explants are significantly upregulated in a dose-dependent manner by the PPARγ agonist rosiglitazone. We also found that PPARγ is induced by rosiglitazone in the same manner and is indispensable for the rosiglitazoneinduced expression and secretion of ANGPTL4. Our results are similar to those reported previously in which rosiglitazone was determined to increase the expression of PPARγ and ANGPTL4. 18, 19 It has been reported that ANGPTL4 is a target gene of PPARγ, 20 and ligand-activated PPARγ regulates the expression of genes via binding to the PPRE of target genes as a heterodimer with RXRs. 15 Therefore, additional studies were performed to elucidate the molecular mechanisms implicated in ANGPTL4 expression induced by rosiglitazone. We provide evidence in HTR8/SVneo cells, HUVECs and placental explants that RXRα is required for the rosiglitazoneinduced expression and secretion of ANGPTL4. In addition, results from our ChIP assay also indicate that the PPARγ/ RXRα heterodimer activates ANGPTL4 transcription by directly binding to PPRE3, located at − 233/ − 209 in its promoter.
PPARγ is required for normal placental development, and its activation regulates trophoblast differentiation and invasion. 7, 21, 22 Previous studies have shown that ANGPTL4 is involved in the regulation of lipid metabolism, wound healing and angiogenesis. 11, 12 Nevertheless, the expression of PPARγ and ANGPTL4 and their correlation are not well characterised in PE and normal pregnancies. We demonstrated in placental tissues and serum that the expression of PPARγ and the expression and secretion of ANGPTL4 were significantly reduced in PE compared with normal control subjects. Our findings that PPARγ expression is decreased in PE subjects are supported by those described previously. 2 In addition, the present study showed that the PPARγ mRNA level is positively correlated with the mRNA level and secretion of ANGPTL4 among normal controls and PE women. A recent study showed that PPARγ activators exist in serum obtained from normal pregnant women and upregulate the expression of PPARγ. 23 This prompted us to investigate the level of PPARγ activators in the serum among PE and normal control subjects. Placental explants treated with serum from five normal and five PE women exhibited upregulated expression of PPARγ and ANGPTL4 in a concentration-dependent manner. These results indicate that PPARγ expression in placental tissue reflects the serum levels of corresponding PPARγ activators in normal controls and PE subjects. Taken together, our findings suggest that the levels of PPARγ activators in the serum are decreased in women with PE. It is important to note that these results are in good agreement with previous observations. 8 In addition, decreased PPARγ activators in the serum may be responsible for the decrease in PPARγ and the expression and secretion of ANGPTL4 in PE.
It is widely accepted that PE is associated with excessive apoptosis and poor invasion of trophoblast cells and limited remodelling of spiral arteries. 3 Therefore, we sought to explore the functional roles of PPARγ and ANGPTL4 in these aspects. Oxidative stress is responsible for increased trophoblast cell apoptosis. 17 In the present study, hydrogen peroxide, an oxidative stress marker, was used to treat HTR8/SVneo cells. The results showed that ANGPTL4 mediated the role of rosiglitazone in anti-apoptosis, accompanying with the decreased expression of genes associated with apoptosis Figure 6 ANGPTL4 plays an important role in rosiglitazone-induced angiogenesis. (a-c) HUVECs transfected with si-Con or si-ANGPTL4 were stimulated with 1 μM rosiglitazone. Control cells were treated with 1 μM rosiglitazone or 100 nM rhANGPTL4. Tube formation assay was performed in these cells, and then the mRNA and protein levels of VEGF and its secretion were evaluated through western blot, qRT-PCR and ELISA. The data are shown as the means ± S.E.M. *Po0.05, **Po0.01 and ***Po0.001 relative to control or si-Con. (d) The expression of PPARγ, ANGPTL4, VEGF and CD31 in placental tissues was examined by IHC in PE subjects (n = 30) and normal controls (n = 30). Representative images were captured at × 400 magnification (cleaved PARP, caspase-9, cleaved caspase-9, caspase-3, cleaved caspase-3 and Bax). Similar to previous findings, 14 we found that ANGPTL4 mediated the facilitative effects of rosiglitazone on trophoblast cells proliferation, with increased expression of proliferation-related genes (Cyclin D1, Bcl-2, c-Myc and pHH3). Moreover, IHC revealed that preeclamptic placental tissue with low expression of PPARγ and ANGPTL4 displayed increased caspase-3 expression and decreased Cyclin D1 expression compared with normal controls.
Given that poor invasion of trophoblast cells and limited remodelling of the spiral arteries are the main pathological features of PE. 3 For migration and invasion, we found that ANGPTL4 mediated the PPARγ agonist-induced the migration and invasion of trophoblast cells and placental explant outgrowth. MMPs are required to create a microenvironment that enables the migration and invasion of trophoblast cells, and decreased MMP-2 and MMP-9 expression in preeclamptic placental tissue has been demonstrated. 24, 25 Analogously, our results suggest that ANGPTL4 mediates PPARγ agonistinduced MMP-2 and MMP-9 expression. Moreover, IHC analysis verified decreased MMP-2 and MMP-9 expression among preeclamptic placental tissues with lower PPARγ and ANGPTL4 levels. VEGF serves as a predominant regulator of angiogenesis and plays a crucial role in the production of blood vessels. 26 Meanwhile, PE is associated with decreased serum level of VEGF and lower microvessel counts in placentas compared with normal controls. 27, 28 Previous studies also provide evidence that ANGPTL4 mediates PPARγ agonist-induced angiogenesis. 13, 18 These data are consistent with our present findings in which ANGPTL4 was determined to be involved in PPARγ agonist-induced angiogenesis by regulating VEGF expression. In addition, decreased expression of VEGF and CD31 were observed in preeclamptic placental tissues with low PPARγ and ANGPTL4 expression.
In summary, we demonstrate that the PPARγ agonist induces ANGPTL4 expression by regulating the binding of the PPARγ/RXRα heterodimer to its promoter region and enhancing its transcriptional activity. Moreover, our data show that the expression and circulating activators of PPARγ and the expression and secretion of ANGPTL4 are decreased in PE subjects. It is worth noting that reduced ANGPTL4 expression and secretion may be attributed to decreased circulating activators of PPARγ in PE. In addition, we provide evidence that ANGPTL4 mediates the facilitative effects of the PPARγ agonist on regulating the survival, proliferation, migration and invasion of HTR8/SVneo cells, placental explant outgrowth and angiogenesis in HUVECs. Previous study has reported that rosiglitazone administration ameliorated hypertension, improved vascular function and prevented the development of several of the pathophysiological characteristics associated with the rat model of PE. 9 Therefore, PPARγ and ANGPTL4 may become potential novel targets for prevention and treatment of PE. However, further studies are required to investigate if PPARγ agonist is effective in prevention and treatment of women with PE. Cell and placental explant culture. HTR8/SVneo (an immortalised human trophoblast cell line) and HUVECs were cultured in DMEM/F12 supplemented with 10% FBS. Placental explants were cultured as previously described. 29, 30 In brief, tissues from first-trimester placental villi were dissected and explanted onto transwell inserts or a 24-well culture dish pre-coated with Matrigel. Explants were Figure 7 Schematic diagram of ANGPTL4 mediated the protective role of PPARγ activators in the pathogenesis of PE. PPARγ agonist induces ANGPTL4 expression by regulating the binding of the PPARγ/RXRα heterodimer to its promoter region and enhancing its transcriptional activity. Moreover, our data show that the expression and circulating activators of PPARγ and the expression and secretion of ANGPTL4 are decreased in PE subjects. In addition, we provide evidence that ANGPTL4 mediates the facilitative effects of the PPARγ agonist on regulating the survival, proliferation, migration and invasion of HTR8/SVneo cells, placental explant outgrowth and angiogenesis in HUVECs permitted to attach to the Matrigel for 4 h and were then supplied with culture medium without serum. Explants were treated with disparate approaches based on the experimental purpose.
RNA extraction and qRT-PCR. Total cellular RNA was extracted using TRIzol reagent according to the manufacturer's instructions. Primers for PPARγ, ANGPTL4, VEGF, Cyclin D1, GAPDH and caspase-3 were obtained from Invitrogen Bioengineering Corporation (Shanghai, China). The sequences of the primers being used for PCR reactions were listed in Supplementary Table 2. qRT-PCR was performed as previously described. 31 Western blot analysis. Protein preparation and western blot analysis were performed as previously described. 31 Antibodies against CK7, PPARγ, ANGPTL4, RXRα, Cyclin D1, Bax, Bcl-2, caspase-3, caspase-9, cleaved caspase-3, cleaved PARP, c-Myc, pHH3, MMP-2, MMP-9, TIMP-1, TIMP-2, β-actin and GAPDH were obtained from Abcam (Cambridge, UK). Antibodies against VEGF and cleaved caspase-9 were obtained from Millipore (Billerica, MA, USA) and Cell Signalling Technology (Boston, MA, USA), respectively.
ELISA. ELISAs (Abcam) were used to detect the levels of ANGPTL4 and VEGF and were performed according to the manufacturer's instructions. The concentration of each sample was determined by measuring the absorbance at 450 nm in a microplate reader. Each sample was run in triplicate.
Immunohistochemical and immunofluorescence staining. IHC and immunofluorescence were performed as previously described. 32 For immunofluorescence analysis, whole mount immunofluorescent staining was performed to confirm the role of PPARγ in ANGPTL4 expression in placental explants. In brief, placental explants cultured for 72 h in the presence of phenol red-free Matrigel were fixed with 4% paraformaldehyde. Subsequently, the explants were washed, blocked, and incubated with the primary antibody and fluorescent secondary antibodies. Ultimately, the fluorescent signals were photographed on an inverted microscope.
ChIP. ChIP was carried out as previously described. 33 Three sets of PCR primers were designed to represent different regions of the ANGPTL4 promoter: PPRE1, PPRE2 and PPRE3. Primer sequences were shown in Supplementary Table 2.
TUNEL and cell proliferation assays. The TUNEL assay was performed according to the manufacturer's instructions (Sigma-Aldrich, St. Louis, MO, USA). Cell proliferation was determined using the Cell Counting Kit-8 (CCK-8) assay (Dojindo, Rockville, MD, USA) according to the manufacturer's instructions.
Transwell invasion and wound-healing assays. Wound healing and transwell invasion assays were executed as previously described. 34 Cell invasion was detected using a cell culture insert (Corning Incorporated, USA) coated with Matrigel (BD Biosciences, San Jose, CA, USA).
Gelatin zymography assay. Gelatin zymography was carried out as previously reported. 32 In brief, the supernatants were collected and electrophoresed on SDS-polyacrylamide gels with 1% gelatin. Subsequently, the gels were washed, incubated, stained and destained successively.
Tube formation assay. The tube formation assay was performed as follows: growth factor reduced Matrigel (BD Biosciences) was placed in a 96-well cell culture plate (60 μl/well) and incubated at 37°C for 30 min. HUVECs transfected with si-Con or si-ANGPTL4 (10 000/200 μl) were seeded onto the Matrigel-coated wells. HUVECs served as a control. Cells were treated with rosiglitazone or recombinant human ANGPTL4 and incubated at 37°C for 20 h. Tube formation was observed under an inverted microscope.
Statistical analysis. All data are shown as mean ± S.E.M. All statistical analyses, including one-way ANOVA, t-test and Pearson's correlation, were executed using SPSS 20.0. All experiments were independently repeated at least in triplicate. Differences between groups were thought to be statistically significant at Po0.05.
